Lexeo Therapeutics, Inc. Operating Cash Flow
Lexeo Therapeutics, Inc. (LXEO) reported Operating Cash Flow of -$38.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Lexeo Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$17.60M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$21.14M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$20.08M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$29.55M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$98.56M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$81.15M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$59.50M.
- Lexeo Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$54.56M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$38.74M 10-Q · filed 2026-08-12 | -$58.82M derived: sum of 3 quarters · filed 2026-08-12 | -$88.37M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$21.14M 10-Q · filed 2026-05-11 | -$41.22M derived: sum of 2 quarters · filed 2026-05-11 | -$70.77M derived: sum of 3 quarters · filed 2026-05-11 | -$97.99M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$20.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$49.63M derived: sum of 2 quarters · filed 2026-03-30 | -$76.84M derived: sum of 3 quarters · filed 2026-08-12 | -$98.56M 10-K · filed 2026-03-30 |
| 2025-09-30 | -$29.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$56.77M derived: sum of 2 quarters · filed 2026-08-12 | -$78.48M 10-Q · filed 2025-11-05 | -$106.81M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$27.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$48.94M 10-Q · filed 2026-08-12 | -$77.26M derived: sum of 3 quarters · filed 2026-08-12 | -$95.07M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$21.72M 10-Q · filed 2026-05-11 | -$50.04M derived: sum of 2 quarters · filed 2026-05-11 | -$67.85M derived: sum of 3 quarters · filed 2026-05-11 | -$88.00M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$28.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$46.13M derived: sum of 2 quarters · filed 2026-03-30 | -$66.28M derived: sum of 3 quarters · filed 2026-03-30 | -$81.15M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$17.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$37.96M derived: sum of 2 quarters · filed 2025-11-05 | -$52.83M 10-Q · filed 2025-11-05 | -$66.81M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$20.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$35.02M 10-Q · filed 2025-08-14 | -$49.00M derived: sum of 3 quarters · filed 2025-08-14 | -$62.95M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$14.87M 10-Q · filed 2025-05-12 | -$28.85M derived: sum of 2 quarters · filed 2025-05-12 | -$42.80M derived: sum of 3 quarters · filed 2025-05-12 | -$55.99M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$13.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$27.93M derived: sum of 2 quarters · filed 2025-03-24 | -$41.12M derived: sum of 3 quarters · filed 2025-03-24 | -$59.50M 10-K · filed 2025-03-24 |
| 2023-09-30 | -$13.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$27.14M derived: sum of 2 quarters · filed 2024-11-13 | -$45.52M 10-Q · filed 2024-11-13 | -$62.14M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$13.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$31.57M 10-Q · filed 2024-08-12 | -$48.19M derived: sum of 3 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$18.37M 10-Q · filed 2024-05-09 | -$35.00M derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | -$16.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$54.56M 10-K · filed 2024-03-11 | ||
| 2022-09-30 | -$37.93M 10-Q · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |